# Bioavailability Study of Midazolam Administered as a Solution by Conventional Syringe or ZENEO®

> **NCT05026567** · PHASE1 · COMPLETED · sponsor: **Crossject** · enrollment: 40 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** 2 ml of DORMICUM® Midazolam Hydrochloride (15 mg/3 mL)
- **COMBINATION_PRODUCT:** ZENEO® Midazolam (10 mg/0.625 mL) on bare skin in thigh
- **COMBINATION_PRODUCT:** ZENEO® Midazolam (10 mg / 0.625 mL) on bare skin in ventrogluteal area
- **COMBINATION_PRODUCT:** ZENEO® Midazolam (10 mg / 0.625 mL) through clothing in thigh

## Key facts

- **NCT ID:** NCT05026567
- **Lead sponsor:** Crossject
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-09
- **Primary completion:** 2022-07-14
- **Final completion:** 2022-07-15
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2022-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05026567

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05026567, "Bioavailability Study of Midazolam Administered as a Solution by Conventional Syringe or ZENEO®". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05026567. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*